JP2015512612A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512612A5 JP2015512612A5 JP2014552348A JP2014552348A JP2015512612A5 JP 2015512612 A5 JP2015512612 A5 JP 2015512612A5 JP 2014552348 A JP2014552348 A JP 2014552348A JP 2014552348 A JP2014552348 A JP 2014552348A JP 2015512612 A5 JP2015512612 A5 JP 2015512612A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- expression
- gene
- level
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 55
- 108090000623 proteins and genes Proteins 0.000 claims 37
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 31
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 31
- 239000005557 antagonist Substances 0.000 claims 31
- 239000012472 biological sample Substances 0.000 claims 28
- 239000000090 biomarker Substances 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 238000002560 therapeutic procedure Methods 0.000 claims 7
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 239000000091 biomarker candidate Substances 0.000 claims 6
- 229960000397 bevacizumab Drugs 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- -1 Col4a2 Proteins 0.000 claims 3
- 230000002491 angiogenic effect Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 230000004043 responsiveness Effects 0.000 claims 3
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100036034 Thrombospondin-1 Human genes 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 108700026220 vif Genes Proteins 0.000 claims 2
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101150066399 COL4A1 gene Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102100021811 E3 ubiquitin-protein ligase RNF5 Human genes 0.000 claims 1
- 102100021860 Endothelial cell-specific molecule 1 Human genes 0.000 claims 1
- 102100023721 Ephrin-B2 Human genes 0.000 claims 1
- 102100032031 Epidermal growth factor-like protein 7 Human genes 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 claims 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 101001107084 Homo sapiens E3 ubiquitin-protein ligase RNF5 Proteins 0.000 claims 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims 1
- 101000897959 Homo sapiens Endothelial cell-specific molecule 1 Proteins 0.000 claims 1
- 101001049392 Homo sapiens Ephrin-B2 Proteins 0.000 claims 1
- 101000921195 Homo sapiens Epidermal growth factor-like protein 7 Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101000972488 Homo sapiens Laminin subunit alpha-4 Proteins 0.000 claims 1
- 102100022743 Laminin subunit alpha-4 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims 1
- 108090000772 Neuropilin-1 Proteins 0.000 claims 1
- 108090000770 Neuropilin-2 Proteins 0.000 claims 1
- 101150034395 Nid2 gene Proteins 0.000 claims 1
- 102000001759 Notch1 Receptor Human genes 0.000 claims 1
- 108010029755 Notch1 Receptor Proteins 0.000 claims 1
- 102100023068 Protein kinase C-binding protein NELL1 Human genes 0.000 claims 1
- 102100034433 Protein kinase C-binding protein NELL2 Human genes 0.000 claims 1
- 238000011529 RT qPCR Methods 0.000 claims 1
- 102100037421 Regulator of G-protein signaling 5 Human genes 0.000 claims 1
- 101710140403 Regulator of G-protein signaling 5 Proteins 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 108700041286 delta Proteins 0.000 claims 1
- 101150109170 dll4 gene Proteins 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586660P | 2012-01-13 | 2012-01-13 | |
| US61/586,660 | 2012-01-13 | ||
| PCT/US2013/021306 WO2013106765A1 (en) | 2012-01-13 | 2013-01-11 | Biological markers for identifying patients for treatment with vegf antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017237944A Division JP2018082705A (ja) | 2012-01-13 | 2017-12-12 | Ｖｅｇｆアンタゴニストで治療するための患者を同定するための生物学的マーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512612A JP2015512612A (ja) | 2015-04-30 |
| JP2015512612A5 true JP2015512612A5 (OSRAM) | 2016-03-03 |
| JP6529261B2 JP6529261B2 (ja) | 2019-06-12 |
Family
ID=48781962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552348A Expired - Fee Related JP6529261B2 (ja) | 2012-01-13 | 2013-01-11 | Ｖｅｇｆアンタゴニストで治療するための患者を同定するための生物学的マーカー |
| JP2017237944A Pending JP2018082705A (ja) | 2012-01-13 | 2017-12-12 | Ｖｅｇｆアンタゴニストで治療するための患者を同定するための生物学的マーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017237944A Pending JP2018082705A (ja) | 2012-01-13 | 2017-12-12 | Ｖｅｇｆアンタゴニストで治療するための患者を同定するための生物学的マーカー |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20130216533A1 (OSRAM) |
| EP (1) | EP2802346B1 (OSRAM) |
| JP (2) | JP6529261B2 (OSRAM) |
| KR (1) | KR20140114415A (OSRAM) |
| CN (1) | CN104203268A (OSRAM) |
| AU (2) | AU2013207778B2 (OSRAM) |
| BR (1) | BR112014017320A2 (OSRAM) |
| CA (1) | CA2862835A1 (OSRAM) |
| HK (1) | HK1204933A1 (OSRAM) |
| IL (2) | IL233467B (OSRAM) |
| MX (1) | MX356802B (OSRAM) |
| NZ (1) | NZ627443A (OSRAM) |
| RU (1) | RU2659173C2 (OSRAM) |
| SG (1) | SG11201403927XA (OSRAM) |
| WO (1) | WO2013106765A1 (OSRAM) |
| ZA (1) | ZA201405305B (OSRAM) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2838086A1 (en) | 2011-06-02 | 2012-12-06 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
| WO2014087156A1 (en) | 2012-12-03 | 2014-06-12 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
| US10456470B2 (en) * | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| GB201409479D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| AU2015229270B2 (en) | 2014-03-12 | 2020-12-24 | Icahn School Of Medicine At Mount Sinai | Method for identifying kidney allograft recipients at risk for chronic injury |
| EP3134119B1 (en) | 2014-04-24 | 2018-08-22 | Pfizer Inc | Cancer treatment |
| GB201409478D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Pro-angiogenic signature |
| GB201409476D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular subtype for use in prognosis |
| CN106661635B (zh) | 2014-06-26 | 2021-05-28 | 西奈山伊坎医学院 | 通过分析预示性基因集诊断亚临床和临床的急性排异的方法 |
| CN106460067A (zh) * | 2014-07-14 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 诊断方法和用于治疗成胶质细胞瘤的组合物 |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| US20170248603A1 (en) * | 2014-10-06 | 2017-08-31 | Dana-Farber Cancer Institute, Inc. | Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response |
| WO2016118670A1 (en) * | 2015-01-20 | 2016-07-28 | Memorial Sloan-Kettering Cancer Center | Multigene expression assay for patient stratification in resected colorectal liver metastases |
| EP3067698A1 (en) | 2015-03-11 | 2016-09-14 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Pd-ecgf as biomarker of cancer |
| EP3274440A4 (en) | 2015-03-27 | 2019-03-06 | Exact Sciences Corporation | Detecting esophageal disorders |
| EP3091084A1 (en) * | 2015-05-08 | 2016-11-09 | Université Catholique De Louvain | Methods for assessing the purity of a mesenchymal stem cells preparation |
| CA3007276C (en) * | 2015-12-03 | 2021-12-28 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitor to treat macular degeneration in a patient population |
| US9845505B2 (en) | 2016-01-29 | 2017-12-19 | BluePrint Bio, Inc. | Prediction of therapeutic response in inflammatory conditions |
| WO2017180581A1 (en) * | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| CA3020718A1 (en) * | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
| JP6799146B2 (ja) * | 2016-10-07 | 2020-12-09 | ベンタナ メディカル システムズ， インコーポレイテッド | 視覚化されたスライド全域画像分析を提供するためのデジタル病理学システムおよび関連するワークフロー |
| JP2018091846A (ja) * | 2016-12-01 | 2018-06-14 | 参天製薬株式会社 | 抗ｖｅｇｆ薬による滲出型加齢黄斑変性の処置の有効性を予測するための方法 |
| ES2953595T3 (es) | 2017-03-01 | 2023-11-14 | Hoffmann La Roche | Procedimientos diagnósticos y terapéuticos para el cáncer |
| US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
| US12070489B2 (en) | 2018-12-12 | 2024-08-27 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with a cancer therapy in combination with another therapeutic agent |
| CA3066053A1 (en) * | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor |
| JP2018049015A (ja) * | 2017-09-26 | 2018-03-29 | マイクロ モーション インコーポレイテッド | 防炎性の電気フィードスルー |
| SG11202007130RA (en) | 2018-01-26 | 2020-08-28 | Univ California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
| EP3773718A4 (en) | 2018-04-06 | 2022-01-19 | aTyr Pharma, Inc. | COMPOSITIONS AND METHODS WITH ANTI-NRP2 ANTIBODIES |
| BR112020019972A2 (pt) | 2018-04-16 | 2021-01-05 | Icahn School Of Medicine At Mount Sinai | Métodos para identificar um receptor de aloenxerto renal e para identificar um receptor de aloenxerto renal em risco de rejeição aguda do aloenxerto antes do transplante, kit para identificar receptores de aloenxerto renal e método para selecionar um paciente com aloenxerto renal |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| WO2021034091A1 (ko) * | 2019-08-19 | 2021-02-25 | 재단법인 아산사회복지재단 | 교모세포종의 진단 방법 |
| EP4037711A4 (en) | 2019-10-03 | 2024-02-14 | Atyr Pharma, Inc. | COMPOSITIONS AND METHODS USING ANTI-NRP2 ANTIBODIES |
| CA3168512A1 (en) | 2019-11-25 | 2021-06-03 | Napoleone Ferrara | Long-acting vegf inhibitors for intraocular neovascularization |
| EP4377674A4 (en) * | 2021-07-28 | 2025-08-06 | Univ California | CELLULAR TYPE OPTIMIZATION METHOD AND SCANNER |
| AU2022327751A1 (en) | 2021-08-11 | 2024-03-21 | OncoHost Ltd. | Predicting patient response |
| CN113834942B (zh) * | 2021-11-02 | 2024-02-02 | 河北特温特生物科技发展有限公司 | 一种胎盘生长因子质控品及其制备方法 |
| CN115840046A (zh) * | 2022-08-17 | 2023-03-24 | 中国药科大学 | 一种鉴别anti-VEGF抗体获得性耐药的蛋白聚糖ESM1生物学标记物及其应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
| DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| WO2001075166A2 (en) | 2000-03-31 | 2001-10-11 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| EP2325205A3 (en) | 2000-12-28 | 2011-10-12 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US7435419B2 (en) | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| EP1743031A4 (en) * | 2004-04-26 | 2008-05-28 | Childrens Medical Center | BLOOD PLATE BIOMARKERS FOR THE DETECTION OF ILLNESSES |
| US20060008823A1 (en) | 2004-05-12 | 2006-01-12 | Kemp Jennifer T | DNA profiling and SNP detection utilizing microarrays |
| RU2517301C2 (ru) | 2006-10-04 | 2014-05-27 | Дженентек, Инк. | Твердофазный иммуноферментный анализ (elisa) для фактора роста эндотелия сосудов (vegf) |
| US20100092485A1 (en) | 2007-01-18 | 2010-04-15 | University Of Southern California | Genetic Markers for Predicting Responsiveness to Combination Therapy |
| EP2065399A1 (en) | 2007-11-30 | 2009-06-03 | Siemens Healthcare Diagnostics GmbH | The present invention relates to methods for prediction of the therapeutic success of breast cancer therapy |
| CA2703258A1 (en) * | 2007-11-09 | 2009-05-14 | Genentech, Inc. | Methods and compositions for diagnostic use in cancer patients |
| US20100029491A1 (en) * | 2008-07-11 | 2010-02-04 | Maike Schmidt | Methods and compositions for diagnostic use for tumor treatment |
| KR20140020368A (ko) | 2008-12-23 | 2014-02-18 | 제넨테크, 인크. | 암 환자에서의 진단 목적용 방법 및 조성물 |
| KR101179843B1 (ko) | 2009-04-08 | 2012-09-04 | 경북대학교 산학협력단 | 뉴로필린 ２의 위암 진단 및 치료용 용도 |
| SG177640A1 (en) | 2009-07-13 | 2012-02-28 | Genentech Inc | Diagnostic methods and compositions for treatment of cancer |
| JP2013501526A (ja) * | 2009-08-14 | 2013-01-17 | ジェネンテック， インコーポレイテッド | Ｖｅｇｆアンタゴニストに対する患者の応答をモニターするための生物学的マーカー |
| US20110064732A1 (en) * | 2009-09-17 | 2011-03-17 | Sanne Lysbet De Haas | Methods and compositions for diagnostic use in cancer patients |
| WO2011088149A2 (en) * | 2010-01-12 | 2011-07-21 | Prometheus Laboratories Inc. | Methods for predicting response of triple-negative breast cancer to therapy |
| EP2525821A1 (en) | 2010-01-19 | 2012-11-28 | F. Hoffmann-La Roche AG | Tumor tissue based biomarkers for bevacizumab combination therapies |
-
2013
- 2013-01-11 MX MX2014008463A patent/MX356802B/es active IP Right Grant
- 2013-01-11 CN CN201380013876.3A patent/CN104203268A/zh active Pending
- 2013-01-11 EP EP13736138.2A patent/EP2802346B1/en not_active Not-in-force
- 2013-01-11 KR KR1020147021823A patent/KR20140114415A/ko not_active Ceased
- 2013-01-11 JP JP2014552348A patent/JP6529261B2/ja not_active Expired - Fee Related
- 2013-01-11 CA CA2862835A patent/CA2862835A1/en not_active Abandoned
- 2013-01-11 RU RU2014133164A patent/RU2659173C2/ru not_active IP Right Cessation
- 2013-01-11 BR BR112014017320A patent/BR112014017320A2/pt not_active IP Right Cessation
- 2013-01-11 WO PCT/US2013/021306 patent/WO2013106765A1/en not_active Ceased
- 2013-01-11 NZ NZ627443A patent/NZ627443A/en not_active IP Right Cessation
- 2013-01-11 SG SG11201403927XA patent/SG11201403927XA/en unknown
- 2013-01-11 HK HK15105537.2A patent/HK1204933A1/xx unknown
- 2013-01-11 AU AU2013207778A patent/AU2013207778B2/en not_active Ceased
- 2013-03-15 US US13/837,343 patent/US20130216533A1/en not_active Abandoned
- 2013-03-15 US US13/836,535 patent/US10364466B2/en not_active Expired - Fee Related
-
2014
- 2014-06-30 IL IL233467A patent/IL233467B/en active IP Right Grant
- 2014-07-18 ZA ZA2014/05305A patent/ZA201405305B/en unknown
-
2017
- 2017-12-12 JP JP2017237944A patent/JP2018082705A/ja active Pending
-
2018
- 2018-01-12 AU AU2018200270A patent/AU2018200270A1/en not_active Abandoned
- 2018-01-24 IL IL257141A patent/IL257141A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512612A5 (OSRAM) | ||
| RU2014133164A (ru) | Биологические маркеры для идентификации пациентов для лечения антагонистами vegf | |
| Wick et al. | Current status and future directions of anti-angiogenic therapy for gliomas | |
| Liebner et al. | Thyroid cancer: pathogenesis and targeted therapy | |
| Torre et al. | New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis | |
| JP2018508469A5 (OSRAM) | ||
| ES2931337T3 (es) | Un método para la identificación de combinaciones de inmunoterapia-fármacos usando un enfoque de red | |
| Charville et al. | Surgical pathology of gastrointestinal stromal tumors: practical implications of morphologic and molecular heterogeneity for precision medicine | |
| JP2012532628A5 (OSRAM) | ||
| RU2012109556A (ru) | Биологические маркеры для мониторирования ответа пациента на антагонисты vegf | |
| US20130252956A1 (en) | Methods of treating cancer | |
| JP2017523776A5 (OSRAM) | ||
| Li et al. | HIF-1α inhibitor YC-1 suppresses triple-negative breast cancer growth and angiogenesis by targeting PlGF/VEGFR1-induced macrophage polarization | |
| Kanda et al. | Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy | |
| Ordóñez-Morán et al. | Complex metastatic niches: already a target for therapy? | |
| Bagnasco et al. | Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors | |
| Cassinello et al. | Role of taxanes in advanced prostate cancer | |
| Méndez-Vidal et al. | SEOM SOGUG clinical guideline for treatment of kidney cancer (2022) | |
| Harari et al. | Sirolimus therapy for patients with lymphangioleiomyomatosis leads to loss of chylous ascites and circulating LAM cells | |
| Sheng et al. | Loss of breast cancer metastasis suppressor 1 promotes ovarian cancer cell metastasis by increasing chemokine receptor 4 expression | |
| Nisa et al. | Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer | |
| Harshman et al. | First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium | |
| Rajhbeharrysingh et al. | Medical therapy for advanced forms of thyroid cancer | |
| JP2014168434A (ja) | 肺癌患者の治療の有効性の予測検査方法及び肺癌治療剤のスクリーニング方法 | |
| Steendam et al. | Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma |